慢性リンパ性白血病治療薬市場：モノクローナル抗体の効果

Abstract

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. Current research is focusing on the urgent unmet need for agents that improve survival. Improved responses from treatment regimens that combine targeted biological agents with established chemotherapy, as well as increased drug therapy for early-stage patients who are likely to progress based on potential prognostic markers, have already begun and will continue to create market opportunities and propel steady growth of the CLL market. In this report, we provide an overview of CLL, including its staging, epidemiology, and biological markers. We discuss the current treatments and promising late-stage agents in development for CLL, as well as the market outlook though 2010.

Table of Contents

• Introduction
• Leukemia
• Characteristics
• Etiology and Pathophysiology
• Symptoms
• Staging and Survival
• Epidemiology
• Prognosis
• Options for Chronic Lymphocytic Leukemia
• Treatment
• Decisions
• Line Therapies
• Second-Line Therapies
• Therapies
• Emerging Therapies for Chronic Lymphocytic
• Leukemia
• Antibodies
• Rituximab
• Lumiliximab
• Other Monoclonal Antibodies
• Immunotoxins
• Inhibitors
• Antisense Oligonucleotides
• Outlook
• Table 1 Common Staging Systems Used in the Treatment of CLL
• Table 2 Select Current Therapies Used for the Treatment of CLL, 2006
• Table 3 NCI Definition of Response to Treatment in CLL Patients
• Table 4 Select Emerging Therapies for the Treatment of CLL in the United States, 2006
• Figure 1 Treatment Algorithm for Chronic Lymphocytic Leukemia